BRIEF published on 10/19/2026 at 10:33, 7 days 4 hours ago Sensorion appoints Peter Weber as Chief Medical Officer Appointment Gene Therapy Hearing Loss Sensory Peter Weber
BRIEF published on 10/19/2026 at 10:33, 7 days 4 hours ago Sensorion nomme Peter Weber au poste de Directeur Médical Nomination Thérapie Génique Sensorion Perte Auditive Peter Weber
PRESS RELEASE published on 10/19/2026 at 10:28, 7 days 4 hours ago Informations privilégiées / Autres communiqués Nomination de Peter Weber, MD, MBA, en tant que Directeur Médical chez Sensorion. Expert en thérapie génique pour surdités génétiques Thérapie Génique Sensorion Directeur Médical Peter Weber Surdité Génétique
BRIEF published on 10/07/2026 at 07:35, 19 days 7 hours ago Louis J. Arcudi III appointed Chief Financial Officer of Sensorion Chief Financial Officer Appointment SENS-601 Sensory Louis J. Arcudi III
BRIEF published on 10/07/2026 at 07:35, 19 days 7 hours ago Louis J. Arcudi III nommé Directeur Financier de Sensorion Nomination Directeur Financier Sensorion SENS-601 Louis J. Arcudi III
PRESS RELEASE published on 10/07/2026 at 07:30, 19 days 7 hours ago Inside Information / Other news releases Sensorion appoints Louis J. Arcudi III as Chief Financial Officer. Arcudi brings extensive biopharmaceutical industry experience to the role Chief Financial Officer Biopharmaceutical Industry Financial Leadership Sensorion Louis J. Arcudi III
PRESS RELEASE published on 10/07/2026 at 07:30, 19 days 7 hours ago Informations privilégiées / Autres communiqués Sensorion annonce la nomination de Louis J. Arcudi III en tant que Directeur Financier, apportant une riche expérience en biopharmaceutique. Il succède à Laurene Danon et travaillera sous la direction de Fred Chereau Biopharmaceutique Directeur Financier Sensorion Fred Chereau Louis J. Arcudi III
BRIEF published on 09/23/2026 at 07:35, 1 month 3 days ago Sensorion Reports 2026 Half-Year Results and Updates Financial Results Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 09/23/2026 at 07:35, 1 month 3 days ago Sensorion publie ses résultats et mises à jour du premier semestre 2026 Résultats Financiers Thérapie Génique Sensorion Perte Auditive SENS-601
PRESS RELEASE published on 09/23/2026 at 07:30, 1 month 3 days ago Informations privilégiées / Communiqué sur comptes, résultats Sensorion publie ses résultats semestriels 2026. Annonce des avancées sur SENS-601, programme de thérapie génique pour la perte auditive. Prévision d'administration au premier patient début 2027 Thérapie Génique Sensorion Perte Auditive SENS-601 Résultats Semestriels 2026
Published on 10/26/2026 at 13:30, 1 hour 18 minutes ago Stabilis Solutions Announces Third Quarter 2026 Conference Call and Webcast Date
Published on 10/26/2026 at 13:00, 1 hour 48 minutes ago BTU Commences Initial Drill Program on Hubcap Project Adjacent to RPX in Wawa
Published on 10/26/2026 at 12:30, 2 hours 18 minutes ago Longview Capital Announces Voluntary TSXV Delisting
Published on 10/26/2026 at 14:36, 12 minutes ago Original-Research: Vossloh AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 10/26/2026 at 14:33, 15 minutes ago UPDATE ON STRATEGIC TRANSACTION, FURTHER PORTFOLIO DISPOSAL PROCESS AND CONTINUED LENDER SUPPORT
Published on 10/26/2026 at 14:28, 20 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 10/26/2026 at 11:27, 3 hours 21 minutes ago 261026 BENETEAU Transactions sur actions propres
Published on 10/26/2026 at 07:30, 7 hours 18 minutes ago EURAZEO’S SUPERVISORY BOARD APPOINTS CHRISTOPHE BAVIÈRE AS CHAIRMAN OF THE EXECUTIVE BOARD AND CEO
Published on 10/26/2026 at 07:30, 7 hours 18 minutes ago LE CONSEIL DE SURVEILLANCE D’EURAZEO NOMME M. CHRISTOPHE BAVIERE PRESIDENT DU DIRECTOIRE
Published on 10/23/2026 at 20:33, 2 days 18 hours ago Déclaration hebdomadaire d'opérations effectuées du 19 au 23 octobre 2026
Published on 10/23/2026 at 20:33, 2 days 18 hours ago Disclosure of transactions in own shares from October 19 to October 23, 2026
